{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:38Z","timestamp":1777452638196,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Because of their high cost, the use of direct-acting antivirals (DAAs) is being restricted by many governments to chronic HCV-infected individuals with advanced liver fibrosis. However, response rates are lower and toxicities more frequent in this subset of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All HIV\u2013HCV-coinfected patients followed for at least 3 years at one reference clinic were identified. Liver fibrosis progression (LFP) was defined as a shift from Metavir F0\u2013F2 to F3\u2013F4 estimates (&gt;9.5 KPa) using elastometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 527 HIV\u2013HCV-coinfected patients were identified, of whom 344 had F0\u2013F2 at baseline. Pegylated interferon\/ribavirin therapy was given to 205 patients with null\/mild fibrosis, of whom 92 (44.9%) achieved sustained virological response (SVR). After a mean follow-up of 53 months, LFP occurred in 5.4% SVR, 25.7% non-SVR and 18% untreated patients ( P=0.005). In multivariate analysis, only achievement of SVR prevented LFP (adjusted hazard ratio 2.1; 95% CI 1.1, 4.1; P=0.01). In 139 untreated patients, only greater baseline elastometry values predicted LFP in multivariate analysis (adjusted hazard ratio 1.84; 95% CI 1.03, 3.3; P=0.03). The area under the receiver operating characteristic (AUROC) curve was 79%. A discriminant threshold of 7.1 kPa gave 68% sensitivity and 82% specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the absence of successful treatment, more than 20% of HIV\u2013HCV-coinfected patients with null\/mild liver fibrosis progress to advanced fibrosis within 5 years. Patients with &gt;7.1 kPa (Metavir F2) display the highest risk. Therefore, all coinfected patients with any significant liver fibrosis should be considered as candidates for new DAA-based therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2816","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T10:11:01Z","timestamp":1403691061000},"page":"799-803","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Progression to Advanced Liver Fibrosis in HIV\u2013HCV-Coinfected Patients and Prioritization of New Hepatitis C Therapies"],"prefix":"10.1177","volume":"19","author":[{"given":"Pablo","family":"Labarga","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose V","family":"Fern\u00e1ndez-Montero","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariola","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"de Mendoza","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"},{"name":"Department of Internal Medicine, Puerta de Hierro Research Institute and Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Sierra-Enguita","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Trevi\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"bibr1-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"bibr2-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70149-X"},{"key":"bibr3-IMP2816","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","volume":"159","author":"Sulkowski M.","year":"2013","journal-title":"Ann Intern Med"},{"key":"bibr4-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"bibr5-IMP2816","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000432466.15885.14"},{"key":"bibr6-IMP2816","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26641"},{"key":"bibr7-IMP2816","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.058"},{"key":"bibr8-IMP2816","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26276"},{"key":"bibr9-IMP2816","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26386"},{"key":"bibr10-IMP2816","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.795543"},{"key":"bibr11-IMP2816","doi-asserted-by":"publisher","DOI":"10.1086\/656811"},{"key":"bibr12-IMP2816","unstructured":"European AIDS Clinical Society Guidelines (EACS). Version 7.0. October 2013. (Accessed 31 January 2014.) Available from http:\/\/www.europeanaidsclinicalsociety.org."},{"key":"bibr13-IMP2816","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12560"},{"key":"bibr14-IMP2816","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12066"},{"key":"bibr15-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"bibr16-IMP2816","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0169-5"},{"key":"bibr17-IMP2816","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"bibr18-IMP2816","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 31 January 2014.) Available from http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf."},{"key":"bibr19-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008"},{"key":"bibr20-IMP2816","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f10de9"},{"key":"bibr21-IMP2816","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23136"},{"key":"bibr22-IMP2816","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2703"},{"key":"bibr23-IMP2816","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12105"},{"key":"bibr24-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.10.011"},{"key":"bibr25-IMP2816","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.009"},{"key":"bibr26-IMP2816","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/135965350601100706","volume":"11","author":"Barreiro P.","year":"2006","journal-title":"Antivir Ther"},{"key":"bibr27-IMP2816","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2419"},{"key":"bibr28-IMP2816","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26741"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:01Z","timestamp":1777380721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.3851\/IMP2816"],"URL":"https:\/\/doi.org\/10.3851\/imp2816","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}